3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
5
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Polycystic Ovary Syndrome
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Venous Thrombosis
1
Triple Negative Breast Neoplasms
1
Rectal Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Ototoxicity
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Prolymphocytic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Inflammation
1
Hodgkin Disease
1
Hemangioma, Cavernous, Central Nervous System
1
Heart Failure
1
Interventions
Exercise
5
Vitamin D
2
Tea
2
Sufentanil
2
Spironolactone
2
Probiotics
2
Oxycodone
2
Omeprazole
2
Morphine
2
Metformin
2
Etanercept
2
Colchicine
2
Ascorbic Acid
2
ziprasidone
1
soybean oil, phospholipid emulsion
1
salicylsalicylic acid
1
ginger extract
1
falcarinol
1
falcarindiol
1
epigallocatechin gallate
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Tumor Necrosis Factors
1
Tranexamic Acid
1
Tobramycin
1
Sulindac
1
Sodium Salicylate
1
Sodium Chloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Inflammation
×
Atorvastatin
×
Clear all
NCT01821404
2018-05-07
ESTO1
Tampere University Hospital
Phase 2
Completed
160 enrolled